Click Here to Go Directly to the Story
Register/Subscribe
Home


 
 

Get Four
Free Issues

Subscribe to BW
Customer Service


Full Table of Contents
Cover Story
Up Front
Editor's Memo
Readers Report
Corrections & Clarifications
Books
Technology & You
Economic Viewpoint
Economic Trends
Industry Insider



Business Outlook
News: Analysis & Commentary
In Business This Week
Washington Outlook
International Business
International Outlook
People
Finance
Working Life
Industrial Management
The Corporation
BusinessWeek Lifestyle
BusinessWeek Investor
The Barker Portfolio
Inside Wall Street
Figures of the Week
Editorials

E.BIZ SUPPLEMENT August 6 Table of Contents

INTERNATIONAL EDITIONS
International -- Readers Report
International -- Asian Business
International -- European Business
International -- Latin America
International -- Int'l Figures of the Week
International -- Editorials




AUGUST 6, 2001

INSIDE WALL STREET

Thoratec: Pumping Up

 
By Gene G. Marcial
Gene Marcial

  STORY TOOLS
Printer-Friendly Version
E-Mail This Story

Related Items Chart: Feeling a Rush


INSIDE WALL STREET

Thoratec: Pumping Up

A Buyer May Pierce Knight's Armor

Starting to Sizzle at Ryan's

Heart failure is getting a lot of attention on the Street. And one company the pros say could become a big player in helping avoid such catastrophes is Thoratec (THOR ). "With its HeartMate ventricular-assist devices, Thoratec will be one of the most important companies in the field," says Dennison Veru of Palisades Capital Management, who is accumulating shares. The stock has swelled from 6 in March to 18 now. Veru thinks it will hit 30 in 12 months.

HeartMate devices take over some of the pumping function of a damaged heart. They are approved in the U.S. and Europe for patients awaiting heart transplants or for use after open-heart surgery. But more important, HeartMate may eventually get Food & Drug Administration approval for use as an alternative to heart transplants--if results from a National Institute of Health-sponsored trial support it.

Thoratec CEO Keith Grossman says: "We are increasingly optimistic" about the potential of HeartMate for treating new patients, who could number 100,000 a year. He explains that implanted devices might permanently assist patients with late-stage heart failure--whose hearts won't recover and who aren't eligible for transplants. This alternative-to-transplant use "is a $2.5 billion-plus market," says Michael Weinstein of J.P. Morgan Securities. He thinks approval could come in a year. He notes that an artificial heart costs some $300,000, while Thoratec's pump device costs $50,000.

Weinstein predicts 2001 earnings of 20 cents a share and 42 cents in 2002. That's in line with Thoratec's forecast: It recently reaffirmed its 2001 revenue estimates at $115 million to $120 million and cash earnings of $9 million to $11 million. In 2002, it sees revenues jumping 25% and cash earnings doubling.



By Gene G. Marcial



Get BusinessWeek directly on your desktop with our RSS feeds.XML

Add BusinessWeek news to your Web site with our headline feed.

Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video.

To subscribe online to BusinessWeek magazine, please click here.

Learn more, go to the BusinessWeekOnline home page

Back to Top

AUGUST
TODAY'S MOST POPULAR STORIES

  1. America's Best Place to Raise Your Kids
  2. These Men Could Kill SarbOx
  3. This Year's Holiday Hit Toy: Zhu Zhu Pets
  4. A Big Loophole in Cap and Trade
  5. Wall Street Plays Hardball

Get Free RSS Feed >>
  MARKET INFO

Portfolio Service Update

Stock Lookup

Enter name or ticker



Media Kit | Special Sections | MarketPlace | Knowledge Centers
McGraw-Hill Cos.